title: Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
abstract: Anti-idiotype (Id) vaccine therapy has been tested and shown to be effective, in several animal models, for triggering the immune system to induce specific and protective immunity against bacterial, viral and parasitic infections. The administration of anti-Id antibodies as surrogate tumor-associated antigens (TAA) also represents another potential application of the concept of the Id network. Limited experience in human trials using anti-Id to stimulate immunity against tumors has shown promising results. In this "counter-point" article, we discuss our own findings showing the potential of anti-Id antibody vaccines to be novel therapeutic approaches to various human cancers and also discuss where anti-Id vaccines may perform better than traditional multiple-epitope antigen vaccines.
authors.affiliation: Department of Internal Medicine, University of Cincinnati, OH 45267-0509, USA. malaya.chatterjee@uc.edu
authors.forename: M
authors.initials: M
authors.lastname: Bhattachary-Chatterjee
authors.forename: R
authors.initials: R
authors.lastname: Nath Baral
authors.forename: S K
authors.initials: SK
authors.lastname: Chatterjee
authors.forename: R
authors.initials: R
authors.lastname: Das
authors.forename: H
authors.initials: H
authors.lastname: Zeytin
authors.forename: M
authors.initials: M
authors.lastname: Chakraborty
authors.forename: K A
authors.initials: KA
authors.lastname: Foon
mesh_terms: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D001943:Breast Neoplasms / Q000628:therapy; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000276:immunology; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000628:therapy; D000939:Epitopes / Q000276:immunology*; D005069:Evaluation Studies as Topic; D005732:Gangliosides / Q000276:immunology; D006017:Glycolipids / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007114:Immunization; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000276:immunology; D066292:Lipid Droplets; D008545:Melanoma / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D018448:Models, Immunological; D018716:Molecular Mimicry; D009369:Neoplasms / Q000517:prevention & control / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen; D000939:Epitopes; D005732:Gangliosides; D006017:Glycolipids; D006023:Glycoproteins; C110367:milk fat globule; C041524:aluminum sulfate; C019403:ganglioside, GD2